Pharmaceutical combinations
View Patent ↗Pharmaceutical combinations suitable for treating the lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) in men are described herein. The combinations contain an alpha-adrenoceptor antagonist and a muscarinic antagonist that may be administered simultaneously, separately or sequentially. The methods of treatment using the combinations are particularly suitable for treating moderate or severe LUTS.
1. A method for treating the lower urinary tract symptoms associated with benign prostate hyperplasia in mammals comprising administering to a mammal suffering from benign prostate hyperplasia an effective amount of an alpha-adrenoceptor antagonist selected of the group of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, alfuzosin, indoramin, maftopidil, tamsulosin, doxazosin, tetrazosin, abanoquil, prazosin, phentolamine, trazodone, dapiprazole and phenoxybenzamine or pharmaceutically acceptable salts thereof in combination with a muscarinic antagonist selected from the group of darifenacin, atropine, fluvoxate, hyoscine, oxybutynin, tolterodine, propantheline, propiverine, and trospium, or pharmaceutically acceptable salts thereof.
2. The method of claim 1 wherein said alpha-adrenoceptor antagonist and said muscarinic antagonist is are administered simultaneously.
3. The method of claim 1 wherein said alpha-adrenoceptor antagonist and said muscarinic antagonist is are administered separately.
4. The method of claim 1 wherein said alpha-adrenoceptor antagonist and said muscarinic antagonist is are administered sequentially.
5. The method of claim 1 wherein the aipha-adrenoceptor antagonist is non-selective or selective for α1 receptors.
6. The method of claim 1 wherein said alpha-adrenoceptor antagonist is selected from the group consisting of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, doxazosin, tetrazosin, abanoquil, prazosin, and indoramin or pharmaceutically acceptable salts thereof.
7. The method of claim 1 wherein said muscarinic antagonist is non-selective or selective for M 3 receptors.
8. The method of claim 1 wherein said muscarinic antagonist is selected from the group consisting of darifenacin, tolterodine and oxybutynin or pharmaceutically acceptable salts thereof.
9. The method of claim 1 wherein said muscarinic antagonist is darifenacin, or a pharmaceutically acceptable salt thereof.
10. The method of claim 1 , wherein said alpha-adrenoceptor antagonist is doxazosin and said muscarinic antagonist is darifenacin, or pharmaceutically acceptable salts of either thereof.
11. The method of claim 1 wherein said alpha-adrenoceptor antagonist is 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl )-5-(2-pyridyl)quinazoline and said muscarinic antagonist is darifenacin, or pharmaceutically acceptable salts of either thereof.